Journal of Clinical Oncology, Volume 44, Issue 17_suppl, Page LBA1-LBA1, June 2026.

Journal of Clinical Oncology, Volume 44, Issue 17_suppl, Page LBA100-LBA100, June 2026.

Journal of Clinical Oncology, Volume 44, Issue 17_suppl, Page LBA1000-LBA1000, June 2026.

Journal of Clinical Oncology, Volume 44, Issue 17_suppl, Page LBA1003-LBA1003, June 2026.

Journal of Clinical Oncology, Volume 44, Issue 17_suppl, Page LBA1006-LBA1006, June 2026.

Journal of Clinical Oncology, Volume 44, Issue 17_suppl, Page LBA1007-LBA1007, June 2026.

Journal of Clinical Oncology, Volume 44, Issue 17_suppl, Page LBA1008-LBA1008, June 2026.

Journal of Clinical Oncology, Volume 44, Issue 17_suppl, Page LBA101-LBA101, June 2026.

Journal of Clinical Oncology, Volume 44, Issue 17_suppl, Page LBA1018-LBA1018, June 2026.

Journal of Clinical Oncology, Volume 44, Issue 17_suppl, Page LBA10509-LBA10509, June 2026.

Journal of Clinical Oncology, Volume 44, Issue 17_suppl, Page LBA12001-LBA12001, June 2026.

Journal of Clinical Oncology, Volume 44, Issue 17_suppl, Page LBA12002-LBA12002, June 2026.

Journal of Clinical Oncology, Volume 44, Issue 17_suppl, Page LBA12003-LBA12003, June 2026.

Journal of Clinical Oncology, Volume 44, Issue 17_suppl, Page LBA12008-LBA12008, June 2026.

Journal of Clinical Oncology, Volume 44, Issue 17_suppl, Page LBA1510-LBA1510, June 2026.

Journal of Clinical Oncology, Volume 44, Issue 17_suppl, Page LBA2-LBA2, June 2026.

Journal of Clinical Oncology, Volume 44, Issue 17_suppl, Page LBA2000-LBA2000, June 2026.

Journal of Clinical Oncology, Volume 44, Issue 17_suppl, Page LBA2007-LBA2007, June 2026.

Journal of Clinical Oncology, Volume 44, Issue 17_suppl, Page LBA3-LBA3, June 2026.

Journal of Clinical Oncology, Volume 44, Issue 17_suppl, Page LBA3500-LBA3500, June 2026.

Journal of Clinical Oncology, Volume 44, Issue 17_suppl, Page LBA3503-LBA3503, June 2026.

Despite recognition that racial and ethnic categories are poor proxies for genetic diversity, race is still used to guide pharmaceutical use, posing risks of ineffectively low or dangerously high dosing.

In a phase 1–2 trial involving patients with acute myeloid leukemia, the use of oral decitabine–cedazuridine with venetoclax induced a complete response in 47% of patients, with expected myelosuppressive effects.

A study dissects the way in which fasting or a fasting-mimicking diet augments the effect of hormonal therapy in a mouse model of breast cancer.

In a patient with recurrent ameloblastoma, zolucatetide (formerly FOG-001) produced an ongoing partial response at 40 weeks, with resolution of solid tumor and cerebral edema. Elevated liver-enzyme levels were noted.

In an African study of severe malaria in children with partially artemisinin-resistant parasites with PfK13 mutations, artesunate did not lead to worse outcomes, which suggests that parenteral artesunate may still be used.

In a phase 3 trial, obexelimab led to a lower risk of disease flares than placebo among patients with IgG4-related disease. Glucocorticoid use was lower and the incidence of remission was higher with obexelimab than with placebo.

IgG4-related disease has emerged as one of the clearest human models for understanding the role of B-lineage cells in immune-mediated inflammation. Although glucocorticoids remain effective for inducing remission, relapse during tapering is common, cumulative toxic effects are substantial, and durable disease control remains difficult to achieve. Della-Torre et al.1

Among patients with previously treated metastatic pancreatic ductal adenocarcinoma, the RAS(ON) inhibitor daraxonrasib led to significantly longer overall survival and progression-free survival than chemotherapy.

In high-risk localized prostate cancer, ADT plus apalutamide led to a pathological complete response or minimal residual disease and 5-year metastasis-free survival in a greater percentage of patients than ADT plus placebo.

Among patients with RET fusion–positive non–small-cell lung cancer, adjuvant selpercatinib led to longer event-free survival than placebo. Adverse events of grade 3 or higher included elevated liver-enzyme levels.

Current curative-intent management of high-risk localized prostate cancer (nonmetastatic prostate cancer with extraprostatic extension or seminal-vesicle invasion, a histologic Gleason score of ≥8 [on a scale from 6 to 10, with higher scores indicating more aggressive disease], or a serum prostate-specific antigen level of ≥20 ng per milliliter) involves either...

In patients with metastatic prostate cancer with gene alterations, talazoparib–enzalutamide led to better progression-free survival outcomes than placebo–enzalutamide but with more serious adverse events.

The treatment of advanced prostate cancer has undergone significant improvements, with two developments proven to be especially transformative. The first advance was the establishment of treatment intensification in patients with metastatic castration-sensitive prostate cancer (hereafter referred to as metastatic androgen pathway modulation–sensitive [APMS] disease, in accordance with the recently updated...

In relapsed multiple myeloma, teclistamab improved 18-month progression-free survival as compared with standard therapy. Grade 3 or 4 infections were common; antimicrobial prophylaxis and immune globulin support were recommended.

In NSCLC with EGFR exon 20 insertions, first-line sunvozertinib led to longer progression-free survival than chemotherapy. The most common adverse events of grade 3 or higher were elevated creatine kinase, diarrhea, and anemia.

The treatment landscape of multiple myeloma has undergone a profound transformation over the past two decades, driven by deeper insights into disease biology, refined patient stratification, the integration of new prognostic biomarkers, and sustained therapeutic innovation. Today, most patients receive proteasome inhibitors, immunomodulatory drugs, and anti-CD38 monoclonal antibodies as frontline...

In HER2-positive gastroesophageal adenocarcinoma, progression-free survival was longer with zanidatamab plus chemotherapy, both with and without tislelizumab, than with trastuzumab plus chemotherapy.

Ugandan children with sickle cell anemia who received 10 years of hydroxyurea therapy had sustained laboratory and clinical benefits, improved growth, and few toxic effects.

Two patients with inborn errors of immunity and progressive multifocal leukoencephalopathy received polyomavirus-specific T cells, followed by allogeneic hematopoietic transplantation with good neurologic outcomes.

Among patients with traumatic hemorrhage, prehospital transfusion of whole blood did not result in lower 30-day mortality than transfusion of plasma or red cells. Outcomes did not differ according to the storage age of blood.

Technological innovations in health care—including artificial intelligence (AI)—have rapidly transformed core components of oncology care. With public health-care systems under substantial financial strain, advancing digital technology has become a game-changing tool in modern oncology workflows. Such technology offers the potential for more precise, efficient, and cost-effective interventions and could help to revolutionise clinical trials, cancer diagnosis, treatment, and health outcomes; reduce waiting times; and ease pressure on health-care services.

Breast radiotherapy is an integral component of breast cancer care to reduce locoregional recurrence.1 Historically, radiotherapy was delivered daily in 25–30 fractions over 5–6 weeks. Radiobiological and technological advances have enabled hypofractionation: shorter courses with larger doses per fraction achieve similar tumour control while reducing late tissue effects through reduced total dose.2 This approach was established in the first generation breast hypofractionation trials,3,4 in which the 3-week regimen (40 Gy in 15 fractions or 42·5 Gy in 16 fractions) matched the tumour control of conventional fractionation with less late tissue effects.

Radioligand therapy, commonly referred to as peptide receptor radionuclide therapy (PRRT), is an established and effective treatment for patients with advanced gastroenteropancreatic neuroendocrine tumours who have progressive disease after previous systemic therapy.1 Treatment selection in patients with progressive advanced gastroenteropancreatic neuroendocrine tumours is multifactorial and guided by primary site, hormonal functionality, symptom burden related to tumour volume, extent of metastatic disease, histological grade, and patient preference.

The Lancet Oncology Commission on the cancer workforce1 presents a stark analysis of an impending global health catastrophe. The Commission projects a workforce shortage of nearly 100 million individuals by 2050. This shortage directly correlates with a widening survival gap between high-income countries (HICs) and low-income and middle-income countries (LMICs). By 2050, Africa's 5-year net survival rate could be nearly half that of HICs, a disparity directly linked to the lack of qualified health professionals.

The Lancet Oncology Commission on the cancer workforce1 makes a case that governments, funders, and policy makers can no longer ignore. It elegantly reframes workforce investment—not as a development aspiration but as an economic imperative. However, a compelling case and a complete one are not always the same thing.

The Lancet Oncology Commission on the cancer workforce1 arrives at a moment of mounting pressure on cancer systems worldwide. However, the workforce crisis is not only a question of numbers, it reflects deeper challenges in how care is organised, delivered, and experienced. Patients, families, and caregivers continue to describe systems that are fragmented, impersonal, and poorly equipped to care for the person beyond the disease. At the same time, burnout and moral injury among oncology professionals are rising, further deepening the workforce crisis.

Workforce disparities in cancer care represent one of the most profound and persistent inequities in global health, with low-income and middle-income countries (LMICs) bearing a disproportionate share of cancer mortality. While high-income countries (HIC) maintain a relatively high number of specialists involved in cancer care, many LMICs struggle with major shortages. This inequality is notably severe for diagnostic specialists, who are 15 times more prevalent in HICs than in low-income regions.

The Lancet Oncology Commission on the cancer workforce1 documents a global crisis in the cancer workforce defined by chronic undersupply, accelerating demand, and health systems increasingly unable to recruit and retain the specialists they need. The UK offers a pointed illustration of how domestic policy choices can compound this challenge.

The Lancet Oncology Commission on the cancer workforce1 is a timely and important examination of the future unmet need for cancer health professionals, and the devastating fiscal and human cost of inaction. In many settings, this crisis is not looming; it has already arrived.

Abdurrahman Hajeer and colleagues published findings from an observational study in which 708 948 cancers were estimated to have required brachytherapy across 185 countries in 2022 (3·8% of incident cases).1 Assuming 218 cases per centre annually, 2246 additional centres would be required by 2050. These findings highlight major inequities in access but do not determine priority setting for cancer control resources.

We read with great interest the OligoPanc consensus by Carl-Stephan Leonhardt and colleagues.1 We congratulate the authors on this landmark interdisciplinary work, which represents the first international effort to standardise the definition of oligometastatic pancreatic ductal adenocarcinoma, and will help harmonise future clinical trials.

We thank Hector Prudhomme and colleagues for their interest in our Article describing a consensus definition of oligometastatic pancreatic ductal adenocarcinoma.1 Para-aortic lymph nodes are an important site of metastasis in pancreatic ductal adenocarcinoma and were therefore explicitly addressed, both in the Delphi process and in vignette three. Although 27 (82%) of 33 respondents to vignette three considered it oligometastatic pancreatic ductal adenocarcinoma, only 32 (56%) of 57 in the Delphi consensus classified para-aortic lymph node metastasis as oligometastasis, thereby meaning that the predefined 75% or greater consensus threshold was not reached.

We read with interest the systematic review and meta-analysis by Alexander H R Varey and colleagues1 assessing the potential survival benefit of sentinel node biopsy (SNB). We also recognise author John F Thompson for a long and accomplished career that successfully established SNB as a routine part of melanoma diagnostics.

We thank Dirk J Grunhagen and colleagues for their interest in our systematic review. We agree that minimising bias is crucial in such studies. Although individual patient data were not available, the Review was rigorously conducted to minimise residual confounding and selection bias through careful study design and appropriate analyses.

Morgans AK, Haresh KP, Jievaltas M, et al. Pain and health-related quality-of-life outcomes with darolutamide in metastatic hormone-sensitive prostate cancer (ARANOTE): secondary and exploratory analyses of a multicentre, randomised, placebo-controlled, phase 3 trial. Lancet Oncol 2026; 27: 614–24—In this Article, the third sentence of the last paragraph of the Results section should have read “The most common grade 3–4 adverse events were hypertension (19 [4%] of 445 patients who received darolutamide vs eight [4%] of 221 patients who received placebo), anaemia (14 [3%] vs eight [4%]), and aspartate aminotransferase increase (ten [2%] vs one [<1%]).” This correction has been made to the online version as of June 1, 2026.

Widder J, Bol GM, Simek I-M, et al. Clinical trial endpoints for metastases-directed therapy in oligometastatic cancer: a review and Delphi consensus on behalf of the EORTC–ESTRO OligoCare consortium. Lancet Oncol 2026; 27: e238–47—In this Policy Review, the table headings should have read “Frequency”. In the Declaration of interests section, statements have been corrected for Helena M Verkooijen and Luca Visani. These corrections have been made to the online version as of June 1, 2026.

Clinicians in England do not have the capacity or headspace to do the innovation needed to deliver the Government's National Cancer Plan, a think tank has warned.

In Thailand, particularly in the northern provinces of the country (eg, Chiang Mai), sustained air pollution, mainly due to persistent wildfires and burning of agricultural waste by farmers, has led to a thick cloud of grey haze and substantial exposure to PM2·5, triggering surges in pollution-related illnesses including cancer.

Almost a fifth of the US population are exposed to potentially cancer-causing nitrates through their drinking water, according to a recent analysis by the Environmental Working Group (EWG).

One in five cancer clinical trials in the USA fail due to insufficient patient enrolment, according to a report from the American Cancer Society Cancer Action Network. Recruitment challenges are pushing researchers overseas, where recruitment is often faster and less expensive, while many eligible US Americans—especially older adults, people from racially minoritised or minority ethnic populations, residents of low-income rural communities, and members of Indigenous communities—cannot afford to participate in potentially life-saving trials, largely because of travel expenses.

On April 27, 2026, US radiation oncologists visited Capitol Hill to tell legislators that the recent policy changes in Medicare have threatened the sustainability of community cancer clinics in the country, as latest data suggested significant economic distress across the field.

David Krug (University Hospital Schleswig-Holstein, Kiel, Germany) presented the first results from a randomised controlled trial showing a progression-free survival benefit from metastasis-directed therapy for patients with oligometastatic breast cancer. In the randomised controlled OLIGOMA trial, patients were randomly assigned to systemic therapy (n=44) or systemic therapy plus stereotactic body radiotherapy (SBRT) to metastatic lesions (n=43). Co-primary endpoints were progression-free survival and quality of life at 12 weeks.

Gaps in patient data reported to the US National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) database by some rural, safety-net, and community hospitals could skew cancer rates and survival outcomes in studies of some of the most vulnerable patient populations. Patients treated at facilities not accredited by the American College of Surgeons Commission on Cancer were two to three times more likely to have missing clinical data in SEER patient records than those treated at Commission on Cancer-accredited centres, researchers reported.

Lung cancer is the leading cause of cancer deaths, causing approximately 1.8 million deaths worldwide.1 Screening with low-dose CT (LDCT) has been shown to significantly reduce lung cancer-specific mortality among populations at high-risk by 20–26%.2 National lung cancer screening programmes have been implemented in several countries and will be introduced in Germany in 2026. Despite these advances, population-level implementation fails to adequately reach those at highest risk;3 globally, lung cancer screening programmes face persistent challenges in achieving equitable access across racial, ethnic, geographic, and socioeconomic groups.

Aglatimagene plus valacyclovir was associated with longer disease-free survival than placebo plus valacyclovir when added to standard of radiotherapy for the treatment of localised prostate cancer, offering a meaningful benefit without increasing clinically significant toxicity.

Long-term follow-up confirms that 26 Gy in five fractions over 1 week is safe and efficacious for adjuvant radiotherapy to the breast or chest wall, supporting its use as a standard of care. Efficacy data for this schedule in the axillary nodal radiotherapy setting are reassuring; however, sample size limits precision of estimation for this subgroup on its own.

Using sunitinib as an internal control, our results show clinically significant antitumour efficacy of [177Lu]Lu-dota-tate in pretreated, progressive, somatostatin receptor-positive, metastatic pancreatic neuroendocrine tumours, and a better quality of life during the treatment phase. Late adverse events were reported in the [177Lu]Lu-dota-tate group that might affect the tolerance of subsequent lines of treatment.

Long-term follow-up supports the safety and local control of SABR for non-surgical patients with renal cell carcinoma, with no observed local recurrences or cancer-related deaths in this cohort, which had predominantly T1b disease or higher.

This pooled analysis from two clinical trials of SABR in patients with larger primary kidney tumours unsuitable for surgery supports evidence of long-term local control and low rate of severe adverse events. These results support further investigation through a randomised trial comparing SABR with surgery in select operable patients.

MRI-guided adaptation for glioblastoma enables margin de-escalation and resulted in a low rate of marginal failure. A randomised trial comparing this technique to a standard large-margin radiotherapy approach will establish whether toxicity and quality-of-life improvements can be realised.

The pandemic's greatest impact was during the first few months of societal lockdowns in 2020 when barriers in access to health care were greatest. Further research is needed to understand whether patients with a missed diagnosis were diagnosed at a later date and if they presented at a later stage.

This breast radiotherapy dosimetry audit shows the feasibility of high-quality large-scale, real-world dosimetric collection and evaluation across the NHS in England. Heart and lung doses predominantly met constraints and were comparable to international benchmarks. However, dosimetric variation existed between centres, particularly in volumetric-modulated arc therapy planning, identifying opportunities for quality improvement.

The shortage of well-trained personnel to deliver cancer care and conduct research remains a major obstacle to reducing disparities in cancer survival between high-income countries and low-income and middle-income countries (LMICs). This Commission set out to provide actionable guidance for strengthening the global cancer workforce with an emphasis on reducing these disparities. To better understand the extent of the rising global cancer burden and the resulting workforce needs, we modelled the current and future global landscape of 17 common cancers and 18 workforce personnel types.

These findings support an association between presence of Fn in CRC tumor tissue and CRC‐specific mortality, particularly for rectal tumors and early‐onset CRC, in a heterogeneous population.

In this secondary analysis of the BLC2001 and THOR trials, higher CTCAE hyperphosphatemia grades were associated with improved OS, PFS, and ORR. These findings suggest that hyperphosphatemia may serve as a potential biomarker of erdafitinib activity, and warrant prospective validation.

This cohort study assesses whether a tiered, evidence-based framework for matching genomic biomarkers to therapies is associated with differential overall survival in patients with advanced solid tumors.

This multicenter, prospective cohort study assesses the diagnostic performance of anti–Epstein-Barr virus (EBV) BNLF2b in outpatients presenting with suspected nasopharyngeal carcinoma, and compares it with the anti-EBV capsid antigen, anti-EBV early antigen, and anti-EBV nuclear antigen 1 assays.

This randomized clinical trial evaluates the efficacy and safety of bireociclib plus fulvestrant in hormone receptor–positive,

This cohort study validates a novel parsimonious, interpretable, and generalizable model for predicting incident pancreatic ductal adenocarcinoma.

This cohort study compares real-world overall survival between sequential and concurrent radiotherapy and immunotherapy among patients with newly diagnosed advanced non–small cell lung cancer.

This secondary analysis of a randomized clinical trial explores treatment outcome preferences among older adults with advanced cancer, specifically whether survival or quality of life matters most to the patient.

This nonrandomized clinical trial examines the safety and efficacy of oral upadacitinib in the treatment of patients with severe immune checkpoint inhibitor–related dermatitis.

This cohort study assesses overall survival without adjuvant therapy in patients with uterine factor–based low-risk endometrial cancer who had isolated tumor cells present in regional lymph nodes.

A 69-year-old male patient presented with worsening new-onset oral ulcerations and pain. He had myelodysplastic syndrome and underwent an allogeneic hematopoietic stem cell transplant 18 months prior. What is your diagnosis?

This Viewpoint discusses national systems implementation of cancer medicines included in the WHO Model Lists of Essential Medicines.

This Viewpoint discusses obesity prevention and control as an underestimated and underutilized strategy in the prevention of numerous cancers.

This Viewpoint discusses insurance barriers to next-generation sequencing (NGS) testing for patients with non–small cell lung cancer and proposes policy solutions to address these barriers.

This Viewpoint discusses increasing the transparency in cancer randomized clinical trials through the use of data and safety monitoring boards.

This

This essay discusses the author’s reflection on his third cancer diagnosis and how he has lived with cancer throughout his life.

June 19, marks World Sickle Cell Day, with the 2026 theme focusing on closing the survival gap and a push towards a universal cure. 20 years have passed since the WHO recognised sickle cell disease as a global health problem, and although some progress has been made, there is clearly still substantial work to be done to improve outcomes for those living with the disease around the world.

The diagnosis of primary CNS lymphoma has traditionally relied on stereotactic brain biopsy, while cytological analysis of cerebrospinal fluid (CSF) or vitreous humour is diagnostic in only a minority of patients.1 Although essential for histopathological confirmation, brain biopsy carries inherent risks, with mortality rates ranging from 0·8% to 2·2%, and might cause substantial delays in treatment initiation.1 Consequently, the development of reliable, less invasive diagnostic approaches has become a major objective in the management of primary CNS lymphoma.

Bone marrow examination is integral to the diagnosis and classification of myeloproliferative neoplasms, but is invasive, can be technically challenging, and is not always immediately feasible. Marie Donzel and colleagues present the Fibrosis Prediction in Bone Marrow using Artificial Intelligence (FIBOM-AI) model,1 a machine learning model trained to predict grade 2–3 bone marrow fibrosis using only age and routine complete blood count (CBC) parameters. Developed from a multicentre cohort using data from 1995 patients with a suspected or established myeloproliferative neoplasm across 13 French centres, and evaluated with both external and prospective validation, this study offers a practical example of how artificial intelligence (AI) can extract insights from routine, inexpensive laboratory data.

Sickle cell disease is one of the most common severe hereditary disorders worldwide. More than 500 000 infants are born with sickle cell disease each year, the majority in sub-Saharan Africa, where early diagnosis and comprehensive care remain limited.1 Advances in neonatal screening and infection prevention have improved survival, but this success has also exposed the growing lifetime burden of cerebrovascular disease.1 Stroke is a leading cause of morbidity, cognitive impairment, and disability in sickle cell disease.

We write as an international group of qualitative researchers working within haematology. We commend Prasanna Ananth and colleagues for their expert recommendations on conducting and appraising qualitative research, including five pillars that support best practice in qualitative studies.1 Quantitative research can tell us what and how much, but qualitative and mixed methods studies help explain why. These approaches are essential for creating and evaluating interventions that work in real-world contexts.

“Where is Talal?” one of the fellows asked.“Probably in the library” another replied with a chuckle.

Chronic lymphocytic leukaemia is often described as indolent—a leukaemia that unfolds slowly, sometimes over decades. In older adults, it behaves less like an acute malignancy and more like a chronic companion. Many patients are diagnosed incidentally and require no immediate therapy. The biology might be calm but the lived experience rarely is.

When Ayako Arai was at medical school in the late 1980s, she became fascinated with the “extraordinary beauty” of blood cells under a microscope. At the time, haematopoietic stem-cell transplantation (HSCT) was just becoming established and the concept of molecular targeted therapy beginning to emerge.

“You Look Fine” begins with LA-based comedian Jared “J” Snow trying a bit of boxing. His trainer holds the mitts and calls the combinations. Jab, right, hook, right, roll, finish with another right. J lands punches, moves competently around the ring, and rests when the bell sounds. After three rounds, he starts feeling discomfort in his chest, so he stops training and goes home to bathe in Epsom salts and swallow some painkillers. He hopes this will be enough to forestall a sickle cell crisis.

Adverse events were few, probably due to organ sparing by total marrow and lymphoid irradiation. Total marrow and lymphoid irradiation 2000 cGy could be safely delivered in combination with high-dose etoposide and cyclophosphamide. The regimen was associated with encouraging 2-year progression-free survival rates.

In this prospective, multicentre cohort of patients with suspected primary CNS lymphoma, we validated the high diagnostic value of MYD88, IL-10, and CXCL13. Results should be interpreted within the full clinical context and with caution, as the diagnostic algorithm and decision tree were derived within the same cohort. In selected clinical scenarios and with further validation of these results, combined CSF biomarker testing might support non-invasive diagnostic decision making and reduce reliance on brain biopsy.

This study showed a high prevalence of post pulmonary embolism syndrome in children with pulmonary embolism. Different clinical factors can contribute, including psychological distress factors and physical limitations, emphasising the need for comprehensive, multidisciplinary care.

FIBOM-AI can be reliably used as a triage and prioritisation tool to support timely bone marrow evaluation or provide complementary risk assessment when bone marrow biopsy is not immediately feasible.

Donor cell-derived haematological neoplasms (DDHN) are rare disorders and currently do not have standardised diagnostic criteria and therapeutic management. International experts in allogeneic transplantation and haematological malignancies from Europe, the Americas, and Australia worked together on behalf of the EBMT Practice Harmonisation and Guidelines Committee to delineate a pragmatic diagnostic framework and issue guidance for downstream clinical management for DDHN. The team met on Sept 18–19, 2025, in Berlin, Germany, to discuss the definition, molecular insights, treatments, and donor outcomes for DDHN after an intensive review of the literature.

Sickle cell disease is a haematological disorder marked by recurrent events and progressive organ dysfunction, yet a standardised framework to assess disease severity is lacking. We developed a novel US-based severity grading system through identification of sickle cell disease-related complications mapping all to the Common Terminology Criteria For Adverse Events and applying a five-level severity scale. A modified Delphi process involving 29 US-based sickle cell disease experts was conducted over three virtual rounds (from Oct 20 to Nov 8, 2023; from June 26 to Aug 1, 2024; and from Nov 6, 2024, to Jan 7, 2025), with the use of a 9-point Likert scale ratings and iterative feedback.

An 83-year-old woman presented to our haematology department in June, 2025, with a 3-month history of palpable cervical lymphadenopathy and splenomegaly. Contrast-enhanced CT revealed enlarged cervical, axillary, inguinal, and visceral lymphadenopathy. A biopsy of a cervical lymph node verified a diagnosis of stage IV angioimmunoblastic T-cell lymphoma (AITL; appendix pp 3–4). Immunohistochemistry showed atypical T cells positive for CD3, CD4, CD10, CD30, ICOS, BCL6, and PD1. In-situ hybridisation for Epstein–Barr virus (EBV)-encoded RNA (EBER) testing was negative (appendix p 7).

Over the past decade, advances in single-cell genomics, lineage tracing, and computational phylogenetics have transformed our understanding of hematopoiesis by enabling detailed reconstruction of hematopoietic stem and progenitor cell clonal relationships across development and aging. Associate Editor Diane S. Krause introduces a comprehensive Review Series on the rapidly evolving field of clonal tracking in hematopoiesis. Rodriguez-Fraticelli outlines key experimental clonal analysis approaches and evaluates their strengths and limitations to guide appropriate method selection for specific biological questions. Tomei and colleagues synthesize clonal lineage–tracing studies to challenge the traditional hierarchical model of stem cell differentiation, proposing alternative frameworks in which lineage bias may arise early and multiple developmental pathways can produce the same mature cell types within phenotypically similar populations. Chen and coauthors explain how DNA methylation can serve as a heritable record of cell division to reconstruct clonal relationships in cancer and how integrating these signals with single-cell data enables reconstruction of tumor evolution while linking lineage history to cellular state and treatment response.

B-cell lymphomas are often driven by altered transcriptional regulation of B-cell development. In this Plenary Paper, Yu and colleagues report that missense mutations in the gene encoding the transcriptional coactivator CREB-binding protein (CREBBP) have a stronger impact on normal germinal center B cells and lymphoma development than truncating mutations, despite both impairing CREBBP function. Missense mutations produce inactive CREBBP proteins that block compensation by the related protein EP300, leading to prolonged germinal center reactions, increased abnormal B-cell growth, and greater lymphoma-promoting effects in mouse models. These findings may help identify patients who could respond better to CREBBP/EP300-targeted therapies.

Over the past decade, advances in single-cell genomics, lineage tracing, and computational phylogenetics have transformed our understanding of hematopoiesis by enabling detailed reconstruction of hematopoietic stem and progenitor cell clonal relationships across development and aging. Associate Editor Diane S. Krause introduces a comprehensive Review Series on the rapidly evolving field of clonal tracking in hematopoiesis. Rodriguez-Fraticelli outlines key experimental clonal analysis approaches and evaluates their strengths and limitations to guide appropriate method selection for specific biological questions. Tomei and colleagues synthesize clonal lineage–tracing studies to challenge the traditional hierarchical model of stem cell differentiation, proposing alternative frameworks in which lineage bias may arise early and multiple developmental pathways can produce the same mature cell types within phenotypically similar populations. Chen and coauthors explain how DNA methylation can serve as a heritable record of cell division to reconstruct clonal relationships in cancer and how integrating these signals with single-cell data enables reconstruction of tumor evolution while linking lineage history to cellular state and treatment response.

Over the past decade, advances in single-cell genomics, lineage tracing, and computational phylogenetics have transformed our understanding of hematopoiesis by enabling detailed reconstruction of hematopoietic stem and progenitor cell clonal relationships across development and aging. Associate Editor Diane S. Krause introduces a comprehensive Review Series on the rapidly evolving field of clonal tracking in hematopoiesis. Rodriguez-Fraticelli outlines key experimental clonal analysis approaches and evaluates their strengths and limitations to guide appropriate method selection for specific biological questions. Tomei and colleagues synthesize clonal lineage–tracing studies to challenge the traditional hierarchical model of stem cell differentiation, proposing alternative frameworks in which lineage bias may arise early and multiple developmental pathways can produce the same mature cell types within phenotypically similar populations. Chen and coauthors explain how DNA methylation can serve as a heritable record of cell division to reconstruct clonal relationships in cancer and how integrating these signals with single-cell data enables reconstruction of tumor evolution while linking lineage history to cellular state and treatment response.

Over the past decade, advances in single-cell genomics, lineage tracing, and computational phylogenetics have transformed our understanding of hematopoiesis by enabling detailed reconstruction of hematopoietic stem and progenitor cell clonal relationships across development and aging. Associate Editor Diane S. Krause introduces a comprehensive Review Series on the rapidly evolving field of clonal tracking in hematopoiesis. Rodriguez-Fraticelli outlines key experimental clonal analysis approaches and evaluates their strengths and limitations to guide appropriate method selection for specific biological questions. Tomei and colleagues synthesize clonal lineage–tracing studies to challenge the traditional hierarchical model of stem cell differentiation, proposing alternative frameworks in which lineage bias may arise early and multiple developmental pathways can produce the same mature cell types within phenotypically similar populations. Chen and coauthors explain how DNA methylation can serve as a heritable record of cell division to reconstruct clonal relationships in cancer and how integrating these signals with single-cell data enables reconstruction of tumor evolution while linking lineage history to cellular state and treatment response.

The phase 3 IMROZ clinical trial showed that adding isatuximab to standard triple therapy significantly improved progression-free survival and increased measurable residual disease (MRD) negativity in newly diagnosed, transplant-ineligible patients with multiple myeloma (MM). Orlowski and colleagues present the results of an analysis of clinical outcomes of this trial according to MRD dynamics by sequential bone marrow MRD measurement, demonstrating that patients receiving the isatuximab-based quadruplet regimen have more favorable MRD dynamics during maintenance therapy, including higher rates of MRD negativity and lower rates of conversion to MRD positivity. These findings reinforce MRD negativity as a key therapeutic objective in MM.

By using patient-derived lymphoma spheroids as an ex vivo platform, Marcoux and colleagues identify key mechanisms of resistance to the bispecific T-cell engager glofitamab in B-cell non-Hodgkin lymphoma, showing that higher CD8 T-cell abundance and cytotoxic activity is associated with better therapeutic responses, while increased T follicular helper (Tfh) cells correlate with resistance. The authors further show that resistance could be overcome by depleting Tfh cells or combining glofitamab with TIGIT (T-cell immunoreceptor with Ig and ITIM domains) blockade, highlighting promising strategies to improve responses to T-cell engager therapies.

The mechanisms of immune modulation by lenalidomide are not fully understood. In this study, Minnie and colleagues identify a suppressive macrophage subset that limits the effectiveness of lenalidomide maintenance therapy after autologous stem cell transplantation in multiple myeloma by restraining cytotoxic natural killer–like CD8 T cells. Blocking the CSF-1 receptor pathway with a Food and Drug Administration–approved antibody reduces these macrophages, enhances T-cell activation, and significantly improves disease control and survival in mouse models when combined with lenalidomide. These findings highlight the complex balance between immune activation and immune regulation during therapy and support the development of combination strategies that strengthen antimyeloma immunity.

T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive hematological malignancy that may arise at different points during T-cell development. Pinton and colleagues reveal the origins of T-ALL by identifying 2 biologically distinct subtypes with T-cell receptors (TCRs) composed of gamma and delta chains (γδ T-ALL): a bona fide early progenitor-derived form, and a more mature cortical-like form caused by abnormal developmental signaling. Bona fide γδ T-ALL subtype strongly overlaps with the high-risk early T precursor and bone marrow progenitor-like signatures associated with treatment resistance. Importantly, these high-risk progenitor-like leukemic cells demonstrate potential sensitivity to venetoclax, highlighting a promising therapeutic vulnerability for difficult-to-treat T-ALL subtypes.

Acute myeloid leukemia (AML) responses to menin inhibitor (MI) monotherapy are often of short duration. Fiskus and colleagues identify novel mechanisms of resistance to MI, showing that resistant leukemia cells become dependent on epigenetic regulator SMARCA4 and BRD4 pathways. The authors further demonstrate that combining the MI revumenib with the SMARCA4/SMARCA2 inhibitor FHD-286 or combining FHD-286 with the BET inhibitor birabresib effectively depletes resistant AML cells and prolongs survival in preclinical models. These findings support the development of rational combination therapies to overcome resistance and improve long-term outcomes in AML.

Hypofibrinogenemia is paradoxically associated with venous and arterial thrombosis by mechanisms that are not fully understood. Lee and coauthors report the absence of thrombosis in a cohort of patients with C-terminus truncating mutations in the gene encoding the fibrinogen α-chain (αC region) and demonstrate that the fibrinogen αC region plays a central role in arterial thrombosis by using mouse and molecular models of vascular injury. Overall, the study suggests that selectively targeting the fibrinogen αC region may offer a promising strategy to prevent both arterial and venous thrombosis while preserving hemostasis.

Kumar and colleagues report preclinical evidence that inhibiting bromodomain and extraterminal (BET) proteins may be an effective strategy for treating chronic graft-versus-host disease (cGVHD) by broadly reprogramming transcriptional inflammatory networks rather than targeting single cytokines. The BET inhibitor modulates multiple disease-driving pathways, including colony-stimulating factor-1 receptor (CSF1R) signaling and auto-/alloreactive antibody responses, suggesting potential advantages over existing therapies such as Janus kinase inhibitors, rho-associated protein kinase inhibitors, and anti-CSF1R antibodies. The authors’ findings highlight BET inhibition as a promising therapeutic strategy for cGVHD.

New England Journal of Medicine, Volume 394, Issue 21, Page 2107-2116, June 4, 2026.

New England Journal of Medicine, Volume 394, Issue 21, Page 2095-2106, June 4, 2026.

New England Journal of Medicine, Volume 394, Issue 21, Page 2083-2094, June 4, 2026.

New England Journal of Medicine, Volume 394, Issue 21, Page 2163-2165, June 4, 2026.

New England Journal of Medicine, Volume 394, Issue 21, Page 2173-2175, June 4, 2026.

New England Journal of Medicine, Volume 394, Issue 21, Page 2175-2176, June 4, 2026.

New England Journal of Medicine, Volume 394, Issue 21, Page 2168-2170, June 4, 2026.

New England Journal of Medicine, Volume 394, Issue 21, Page 2158-2159, June 4, 2026.

New England Journal of Medicine, Volume 394, Issue 21, Page 2147-2154, June 4, 2026.

New England Journal of Medicine, Volume 394, Issue 21, June 4, 2026.

New England Journal of Medicine, Volume 394, Issue 21, June 4, 2026.

New England Journal of Medicine, Volume 394, Issue 21, Page 2076-2079, June 4, 2026.

New England Journal of Medicine, Volume 394, Issue 21, June 4, 2026.

New England Journal of Medicine, Ahead of Print.

New England Journal of Medicine, Ahead of Print.

New England Journal of Medicine, Ahead of Print.

New England Journal of Medicine, Ahead of Print.

New England Journal of Medicine, Ahead of Print.

New England Journal of Medicine, Ahead of Print.

New England Journal of Medicine, Ahead of Print.

New England Journal of Medicine, Ahead of Print.

New England Journal of Medicine, Ahead of Print.

New England Journal of Medicine, Ahead of Print.

New England Journal of Medicine, Ahead of Print.

New England Journal of Medicine, Ahead of Print.

New England Journal of Medicine, Ahead of Print.

New England Journal of Medicine, Ahead of Print.

New England Journal of Medicine, Ahead of Print.

New England Journal of Medicine, Ahead of Print.

New England Journal of Medicine, Ahead of Print.

New England Journal of Medicine, Ahead of Print.

New England Journal of Medicine, Ahead of Print.

New England Journal of Medicine, Ahead of Print.

New England Journal of Medicine, Ahead of Print.

New England Journal of Medicine, Ahead of Print.

New England Journal of Medicine, Ahead of Print.

The investigational multiselective RAS(ON) inhibitor daraxonrasib may represent a new standard second-line treatment option for patients with metastatic pancreatic ductal adenocarcinoma, according to results from the phase III RASolute 302 trial. In the study, presented by Brian Wolpin, MD, MPH, of ...

As reported at the 2026 ASCO Annual Meeting and in The New England Journal of Medicine by Touzeau et al, an interim analysis of the phase III MajesTEC-9 trial has shown improved progression-free survival with teclistamab vs investigator's choice of pomalidomide, bortezomib, and dexamethasone (PVd)...

As reported at the 2026 ASCO Annual Meeting and in The New England Journal of Medicine by Agarwal et al, the phase III TALAPRO-3 trial has shown improved imaging-based progression-free survival with the addition of talazoparib to enzalutamide in patients receiving androgen-deprivation therapy for...

As reported in The Lancet Oncology by Siva et al, 5-year findings in a pooled analysis of the FASTRACK and FASTRACK II trials support evidence of maintained disease control with ultra-hypofractionated stereotactic ablative body radiotherapy (SABR) in patients with primary renal cell carcinoma...

As reported at the 2026 ASCO Annual Meeting and in The New England Journal of Medicine by Zhou et al, the phase III WU-KONG28 trial has shown that first-line sunvozertinib improved progression-free survival vs chemotherapy in patients with advanced nonsquamous non–small cell lung cancer (NSCLC)...

On May 28, 2026, the U.S. Food and Drug Administration (FDA) approved the PD-L1 inhibitor durvalumab (Imfinzi) in combination with bacillus Calmette-Guérin (BCG) for the treatment of adult patients with BCG-naive, high-risk non–muscle-invasive bladder cancer (NMIBC).

On May 15, the U.S. Food and Drug Administration (FDA) approved the PD-L1 inhbitor atezolizumab (Tecentriq) and atezolizumab and hyaluronidase-tqjs (Tecentriq Hybreza) as adjuvant therapies for adults with muscle-invasive bladder cancer (MIBC) after cystectomy who have circulating tumor DNA...

Black women experience disproportionately elevated risks of developing and dying from early-onset breast cancer. New research published by Beasley et al in Cancer reveals the genes that are most likely to be mutated to contribute to these increased risks.

An all-oral treatment regimen led to complete responses in almost half of all patients with newly diagnosed acute myeloid leukemia (AML) who were ineligible for intensive chemotherapy, according to findings from the phase I/II ASCERTAIN V trial published in The New England Journal of Medicine. 

A major real-world study has found serious blood-related side effects associated with antibody-drug conjugates (ADCs), an increasingly important class of targeted cancer therapies. Over the years, many novel ADC therapies have been approved for treating various types of cancers.

In an individual patient analysis reported in the Journal of Clinical Oncology, Moon et al found that treatment of early-stage hepatocellular carcinoma (HCC) with external-beam radiation therapy (EBRT) was associated with survival outcomes comparable to other treatment modalities such as surgical...

In a Chinese retrospective cohort study reported in the Journal of Clinical Oncology, Lu et al found that adding brain radiotherapy to continued original systemic therapy produced better outcomes compared to brain radiotherapy and substitution of systemic therapy or substitution of systemic therapy ...

Results from the first randomized controlled trial evaluating a multicancer early detection (MCED) blood test suggest that annual screening with the Galleri test may alter the stage at which cancers are diagnosed, reducing the burden of stage IV cancers. However, the study did not achieve its...

Exposure to glucagon-like peptide-1 receptor agonists (GLP-1 RAs) may lower the risk of breast cancer incidence, according to findings from a retrospective analysis presented at the 2026 ASCO Annual Meeting (Abstract 10506). The findings were also published in JCO Oncology Practice. 

The American Cancer Society (ACS) recently released updated guidelines for colorectal cancer screening. The new recommendations reaffirm that average-risk adults should begin colorectal cancer screening at age 45 years and continue through age 75 years for those with a life expectancy greater than...

In an analysis reported in The Lancet, Dreyling et al provided long-term findings with three first-line regimens in the phase III TRIANGLE trial among patients aged 18 to 65 years with mantle cell lymphoma.

A new study from Cleveland Clinic researchers confirms that tissue-derived tumor mutation burden (TMB) remains the more reliable predictor of immunotherapy response in patients with solid tumors. Results were presented at the 2026 ASCO Annual Meeting (Abstract 2580).

Online resources for patients and the general public focused on artificial intelligence (AI) and its uses in cancer research and cancer care were found lacking in a cross-sectional analysis presented at the 2026 ASCO Annual Meeting (Abstract 9000). The study highlighted that the existing webpages...

The combination of the individualized neoantigen therapy intismeran autogene and pembrolizumab led to an improvement in recurrence-free survival and distant metastasis–free survival rates compared with pembrolizumab alone in patients with high-risk resected melanoma, according to 5-year results...

Individuals with estrogen receptor–positive, HER2-negative, high-risk early breast cancer and low Prosigna (PAM50) risk of recurrence (ROR) scores of 60 or less were able to safely skip chemotherapy, according to findings from a randomized, noninferiority phase III trial presented at the 2026 ASCO...

Friends of Cancer Research announced the election of Richard Pazdur, MD, to its Board of Directors. Dr. Pazdur spent 26 years at the U.S. Food and Drug Administration, where he served as the founding director of the Oncology Center of Excellence and played a leading role in shaping the regulatory...

A comprehensive Cochrane review presented at the 2026 ASCO Annual Meeting suggests that commonly used breast cancer risk prediction models provide only modest accuracy in identifying which women with a family history of breast cancer will ultimately develop the disease (Abstract 10545). Although...

Longer follow-up from the phase III NRG-GY018 trial continues to support the addition of pembrolizumab to standard carboplatin/paclitaxel chemotherapy for patients with primary advanced-stage or recurrent endometrial cancer, according to findings presented during the Gynecologic Oncology Session at ...

A phase III randomized trial presented at the 2026 ASCO Annual Meeting found that implanted tile-based radiation therapy significantly reduced local recurrence and improved overall survival compared with postoperative stereotactic radiotherapy (SRT) in patients undergoing surgical resection of...

Right ventricle (RV) dysfunction is associated with poorer outcomes in heart failure with preserved ejection fraction (HFpEF). Females are more likely to have HFpEF but males have worse prognosis and resting RV function. The contribution of dynamic RV-pulmonary artery (RV-PA) coupling between sex and its impact on peak exercise capacity (VO2) in HFpEF is not known.

A Phase I, single-center investigation demonstrated that 8 weeks of antimycobacterial therapy improved sarcoidosis forced vital capacity (FVC). Safety and efficacy assessments have not been performed in a multicenter cohort.

All aspects of medical education were affected by the Novel Coronavirus Infectious Disease-19 (COVID-19) pandemic. Several challenges were experienced by trainees and programs alike due to the economic repercussions of the pandemic, how social distancing affected the delivery of medical education, testing and interviewing, how the surge of patients affected redeployment of personnel, potential compromise in core training and the overall impact on the wellness and mental health of trainees and educators.

In this meta-analysis of observational studies, RV dysfunction was associated with higher short-term and long-term mortality in sepsis and septic shock.

Legionella is an uncommon cause of CAP, occurring primarily from late spring through early autumn. Testing is uncommon, even among patients with risk factors, and many positive patients failed to receive empiric coverage for LP.

The nS classification could be used to provide a more accurate prognosis in patients with resected NSCLC. The nS is worth taking into consideration when defining nodal category in the forthcoming ninth edition of the staging system.

NLP successfully identified a large cohort with CC. Most patients were identified through NLP alone, rather than diagnoses or medications. NLP improved detection of patients nearly seven-fold, addressing the gap in ability to identify and characterize CC disease burden. Nearly all cases appeared to be managed in primary care. Identifying these patients is important for characterizing treatment and unmet needs.

Pulmonary arterial hypertension (PAH) is a rare disease and much of our understanding stems from single-center studies, which are limited by sample size and generalizability. Administrative data offer an appealing opportunity to inform clinical, research, and quality improvement efforts for PAH. Yet, there is currently no standardized, validated method to distinguish PAH from other subgroups of pulmonary hypertension (PH) within this data source.

A transparent DL algorithm improves on traditional clinical criteria to predict the need for MV in hospitalized patients, including in those with COVID-19. Such an algorithm may help clinicians optimize timing of tracheal intubation, better allocate resources and staff, and improve patient care.

To assess airway and lung parenchymal damage non-invasively in cystic fibrosis (CF), chest MRI has been historically out of the scope of routine clinical imaging due to technical difficulties such as the low proton density and respiratory and cardiac motion. However, technological breakthroughs have recently emerged to dramatically improve lung MRI quality (including signal-to-noise ratio, resolution, speed, contrast). At the same time, novel treatments have changed the landscape of CF clinical care.

Bronchoscopic lung volume reduction with one-way endobronchial valves is a guideline treatment option for patients with advanced emphysema, supported by extensive scientific data. Patients limited by severe hyperinflation, with a suitable emphysema treatment target lobe and with absence of collateral ventilation are the responders to this treatment. Detailed patient selection, a professional treatment performance, and dedicated follow-up of the valve treatment, including management of complications, are key ingredients to success.

Chronic Obstructive Pulmonary Disease (COPD) may cause profound dyspnea, functional impairment, and reduced quality of life. Available pharmacologic therapy provides suboptimal symptom improvement in many patients. Bronchoscopic lung volume reduction (BLVR), achieved with endobronchial valve (EBV) placement, can effectively improve dyspnea and functional status in appropriately selected patients. Operationalizing a safe and effective BLVR program requires appropriate oversight which can be achieved by a BLVR Nurse Coordinator (NC).

Empathy-based, stigma-reducing communication may lead to improved assessments of tobacco use and smoking cessation for patients with smoking-related cancers. These findings support the dissemination and further testing of a new ECS model for training OCPs in best practices for assessment of smoking history and engagement of patients who currently smoke in tobacco treatment delivery.

In clinical practice, reslizumab may have been initiated in response to heavy symptom burden and CAEs. Reslizumab was associated with improved clinical and patient-reported outcomes and significant reductions in asthma-related HRU.

Quantitative emphysema measured on LDCT of the chest can be leveraged to improve lung cancer risk prediction and help diagnose COPD in individuals who currently or formerly smoked undergoing lung cancer screening.

Ciltacabtagene autoleucel (cilta-cel) has transformed the outcomes of patients with relapsed or refractory multiple myeloma, yet its toxicity profile — spanning acute and delayed-onset neurotoxicity, secondary malignancies, immune effector-cell colitis, infections and prolonged cytopenias — has emerged slowly. As safer alternatives become available, the risk–benefit calculus for cilta-cel demands urgent reassessment, particularly in earlier lines of therapy.

The Australian Pharmaceutical Benefits Advisory Committee’s decision to allow tumour-agnostic reimbursement of nivolumab and ipilimumab is a bold experiment that involves a considerable level of risk-sharing between government, industry, clinicians and patients. The central policy challenge now is whether Australia has sufficient infrastructure and initiative to convert this access into timely and decision-relevant evidence. Reimbursement that accelerates access despite uncertainty carries an obligation to learn.

Ibrutinib improves overall survival in patients with mantle cell lymphoma

First-line zanidatamab–chemotherapy with or without tislelizumab improves survival in advanced-stage HER2⁺ GEA

Kidney injury molecule-1 (KIM-1) is overexpressed in renal cell carcinoma (RCC), and consistent shedding of this cell-surface protein into the circulation makes it a promising blood-based biomarker for this disease. Herein, we outline potential roles of circulating KIM-1 in diagnosis, prognostication and therapeutic monitoring of RCC, as well as research priorities for clinical translation of this biomarker.

The management of gastro-oesophageal adenocarcinoma (GEA) is undergoing substantial changes owing to evolving treatment paradigms and new therapeutic strategies on the background of a shifting global epidemiology. This Review discusses the state-of-the-art perioperative management of resectable GEA, with an emphasis on how biological heterogeneity influences geographical practice patterns, and outlines future directions for research including precision medicine approaches, biomarker-guided immunotherapy and tailored surgical approaches.

Pan-RAS inhibitor daraxonrasib shows promise in pancreatic cancer

On 3 February 2026, the Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act was enacted, enabling Medicare coverage for multi-cancer early detection (MCED) tests. This legislation coincides with new results from key clinical trials and has important implications for payers and policymakers, given the lack of FDA approval of any MCED test or evidence that population screening with such tests reduces cancer-related or all-cause mortality.

Annals of Internal Medicine, Volume 179, Issue 5_Supplement, May 2026. <br/>

Annals of Internal Medicine, Volume 179, Issue 5_Supplement, May 2026. <br/>

Annals of Internal Medicine, Volume 179, Issue 5_Supplement, May 2026. <br/>

Annals of Internal Medicine, Volume 179, Issue 5_Supplement, May 2026. <br/>

Annals of Internal Medicine, Volume 179, Issue 5_Supplement, May 2026. <br/>

Annals of Internal Medicine, Volume 179, Issue 5_Supplement, May 2026. <br/>

Annals of Internal Medicine, Volume 179, Issue 5_Supplement, May 2026. <br/>

Annals of Internal Medicine, Volume 179, Issue 5_Supplement, May 2026. <br/>

Annals of Internal Medicine, Volume 179, Issue 5_Supplement, May 2026. <br/>

Annals of Internal Medicine, Volume 179, Issue 5, Page 621-628, May 2026. <br/>

Annals of Internal Medicine, Volume 179, Issue 5, Page 629-636, May 2026. <br/>

Annals of Internal Medicine, Volume 179, Issue 5, Page 637-644, May 2026. <br/>

Annals of Internal Medicine, Volume 179, Issue 5, Page 645-655, May 2026. <br/>

Annals of Internal Medicine, Volume 179, Issue 5, Page 656-665, May 2026. <br/>

Annals of Internal Medicine, Volume 179, Issue 5, Page 666-672, May 2026. <br/>

Annals of Internal Medicine, Volume 179, Issue 5, Page 673-684, May 2026. <br/>

Annals of Internal Medicine, Volume 179, Issue 5, Page 685-695, May 2026. <br/>

Annals of Internal Medicine, Volume 179, Issue 5, Page 696-707, May 2026. <br/>

Annals of Internal Medicine, Volume 179, Issue 5, Page 708-720, May 2026. <br/>

Annals of Internal Medicine, Volume 179, Issue 5, Page 728-733, May 2026. <br/>

Annals of Internal Medicine, Volume 179, Issue 5, Page 734-739, May 2026. <br/>

Annals of Internal Medicine, Volume 179, Issue 5, Page 721-724, May 2026. <br/>

Annals of Internal Medicine, Volume 179, Issue 5, Page 725-727, May 2026. <br/>

Annals of Internal Medicine, Volume 179, Issue 5, Page 740-741, May 2026. <br/>

Annals of Internal Medicine, Volume 179, Issue 5, Page 742-743, May 2026. <br/>

Annals of Internal Medicine, Volume 179, Issue 5, Page 744-745, May 2026. <br/>

When used alongside Merck’s Keytruda, Moderna’s personalized cancer vaccine halved the risk of death or disease recurrence in a mid-stage trial of advanced melanoma—a result analysts said could help “instill confidence” in the regimen.

In addition to eliciting 17.3 months median overall survival vs. 8.5 months for patients given standard of care treatment in a prior study, Immuneering’s atebimetinib demonstrated a robust tolerability profile—something CEO Ben Zeskind said equates highly with survival.

Apogee’s pipeline in a product drug zumilokibart achieved significant disease clearance in a mid-stage atopic dermatitis trial, but investors were miffed by a royalty financing deal with Blackstone.

Biogen and Denali’s Parkinson’s disease drug failed to significantly slow disease progression in a Phase 2b study, missing both primary and secondary endpoints.

Analysts are extremely encouraged by Phase 2 trial results for Relay Therapeutics’ PI3KA inhibitor in treating vascular malformations (VM), prompting the biotech to eye a potential path to accelerated approval.

While Biogen’s tau-targeting therapy didn’t demonstrate improvement on a dementia severity scale, the company touted biomarker and cognitive improvements from the Phase 2 study, leaving analysts eager for more data.

Entrada Therapeutics saw a 2.36% dystrophin increase in patients treated with its oligonucleotide asset—a number that fell short of the company’s prior guidance of a double-digit improvement.

Pfizer-backed cancer company CellCentric will use the cash to support the launch of a pivotal myeloma trial testing its potentially first-in-class oral treatment this year.

Johnson & Johnson plans to advance the co-antibody therapy, which combines its IL-23 blocker Tremfya and the TNF-alpha inhibitor Simponi, into late-stage testing for Crohn’s disease and ulcerative colitis.

Corcept Therapeutics’ amyotrophic lateral sclerosis drug was linked to an 87% reduction in the risk of death, a result the biotech hopes to replicate in an upcoming Phase 3 trial.

By inhibiting the APRIL cascade, Otsuka Pharmaceuticals’ Voyxact slowed kidney function decline in patients with IgAN, opening up a potential path for full approval while also reading through to Vertex and others with similar assets.

In addition to a high rate of deaths, ADC Therapeutics’ Zynlonta plus rituximab showed no overall survival benefit in patients with diffuse large B cell lymphoma, casting doubt on its value as a second-line treatment in this indication.

Celcuity’s gedatolisib doubled progression-free survival versus standard of care in certain patients with advanced breast cancer. Still, the biotech’s stock dropped more than 25% Tuesday.

Merck may not have had the splashiest presentation at the American Society of Clinical Oncology meeting, but the data show why the Big Pharma remains king of oncology, analysts say.

Interim overall survival data on a TROP2 ADC from Merck and Chinese partner Kelun-Biotech provide support for the pharma’s big bet on its potential to help navigate Keytruda’s impending loss of exclusivity.

Revolution Medicines and its RAS inhibitor daraxonrasib stole the show at the American Society of Clinical Oncology’s annual meeting this weekend, as Truist Securities predicts a possible third quarter launch for the pancreatic cancer drug.

Analysts, investors and partner Summit Therapeutics had all been keenly awaiting the overall survival update, after previous data from Akeso’s HARMONi-6 trial left them wanting.

As Summit Therapeutics’ Chinese partner prepares to reveal data for a key trial at ASCO, analysts consider the impact on rivals Merck, Bristol Myers Squibb and BioNTech.

The antisense oligonucleotide was even more effective in patients with relatively low viral activity. More than one-quarter of these individuals had undetectable levels of the virus in the blood for at least six months after stopping treatment.

Treatment with the TROP2 ADC sac-TMT led to a 70% objective response rate and progression-free survival was “significantly improved” as compared to placebo—the second positive readout for the asset this week.

By inhibiting the APRIL cascade, Otsuka Pharmaceuticals’ Voyxact slowed kidney function decline in patients with IgAN, opening up a potential path for full approval while also reading through to Vertex and others with similar assets.

In addition to a high rate of deaths, ADC Therapeutics’ Zynlonta plus rituximab showed no overall survival benefit in patients with diffuse large B cell lymphoma, casting doubt on its value as a second-line treatment in this indication.

In this episode of Denatured, you’ll be hearing from Daniel Gil, CEO of Pelage Pharmaceuticals and Francisco Ramírez-Valle, senior vice president of immunology discovery at Eli Lilly. We dive into the long-overlooked hair loss space, exploring why true innovation has lagged, how a regenerative approach aims to reactivate dormant follicles and what early proof-of-concept means for patients.

Celcuity’s gedatolisib doubled progression-free survival versus standard of care in certain patients with advanced breast cancer. Still, the biotech’s stock dropped more than 25% Tuesday.

All six non-Hodgkin lymphoma patients on Legend Biotech’s CAR T therapy responded to treatment—findings that could make the biotech an attractive takeover target, according to analysts at Oppenheimer.

Improved survival on display at the American Society of Clinical Oncology (ASCO) in Chicago; Pfizer’s unusual pact with China’s Innovent highlights a new type of collaboration; Eli Lilly continues its nonstop deal streak, including with Chinese biotechs; and looking ahead to this weekend’s American Diabetes Association meeting.

Merck may not have had the splashiest presentation at the American Society of Clinical Oncology meeting, but the data show why the Big Pharma remains king of oncology, analysts say.

When used alongside Merck’s Keytruda, Moderna’s personalized cancer vaccine halved the risk of death or disease recurrence in a mid-stage trial of advanced melanoma—a result analysts said could help “instill confidence” in the regimen.

Government backing, deep scientific talent and a robust pharma heritage are helping France punch above its weight, but turning research into investable companies remains a challenge.

In addition to eliciting 17.3 months median overall survival vs. 8.5 months for patients given standard of care treatment in a prior study, Immuneering’s atebimetinib demonstrated a robust tolerability profile—something CEO Ben Zeskind said equates highly with survival.

On May 28, 2026, the Food and Drug Administration approved durvalumab (Imfinzi, AstraZeneca) in combination with Bacillus Calmette-Guerin (BCG) for the treatment of adult patients with BCG-naïve, high-risk non-muscle invasive bladder cancer (NMIBC).

On May 27, 2026, the Food and Drug Administration approved pivekimab sunirine-pvzy (Decnupaz, AbbVie, Inc.), a CD123-directed antibody and alkylating agent conjugate, for adults with blastic plasmacytoid dendritic cell neoplasm (BPDCN).

On May 22, 2026, the Food and Drug Administration approved datopotamab deruxtecan-dlnk (Datroway, Daiichi Sankyo, Inc.) for adult patients with unresectable or metastatic triple-negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy.

On May 15, 2026, the Food and Drug Administration (FDA) approved fam-trastuzumab deruxtecan-nxki (T-DXd, Enhertu, Daiichi Sankyo, Inc.) for two separate indications in adults with HER2-positive early-stage breast cancer. The first indication is for T-DXd followed by a taxane, trastuzumab, and pertuzumab (THP), for the neoadjuvant treatment of adult patients with HER2-positive (IHC 3+ or ISH+) Stage II or III breast cancer, as determined by an FDA-authorized test. The second indication is for T-DXd for the adjuvant treatment of adult patients with HER2-positive (IHC 3+ or ISH+) breast cancer who have residual invasive disease following neoadjuvant treatment with trastuzumab (with or without pertuzumab) and taxane-based treatment.

On May 15, 2026, the Food and Drug Administration approved atezolizumab (Tecentriq, Genentech, Inc. and atezolizumab and hyaluronidase-tqjs (Tecentriq Hybreza, Genentech, Inc.) as adjuvant treatments for adults with muscle invasive bladder cancer (MIBC) after cystectomy who have circulating tumor DNA molecular residual disease (ctDNA MRD) as determined by an FDA-authorized test.

On May 13, 2026, the Food and Drug Administration approved an oral combination of decitabine and cedazuridine tablets (Inqovi, Taiho Oncology, Inc.) with venetoclax for the treatment of newly diagnosed acute myeloid leukemia (AML) in adults 75 years or older, or who have comorbidities that preclude the use of intensive induction chemotherapy.

On May 13, 2026, the Food and Drug Administration granted accelerated approval to sonrotoclax (Beqalzi, BeOne Medicines USA, Inc.), a BCL-2 inhibitor, for adults with relapsed or refractory mantle cell lymphoma (MCL) after at least two lines of systemic therapy, including a Bruton’s tyrosine kinase (BTK) inhibitor.

On May 8, 2026, the Food and Drug Administration approved zenocutuzumab-zbco (Bizengri, Partner Therapeutics, Inc.) for adults with advanced, unresectable or metastatic cholangiocarcinoma harboring a neuregulin 1 (NRG1) gene fusion with disease progression on or after prior systemic therapy. NRG1-fusion positive cholangiocarcinoma is an extremely rare, life-threatening malignancy.

On May 1, 2026, the Food and Drug Administration approved vepdegestrant (Veppanu, Arvinas Operations, Inc.), a heterobifunctional protein degrader, for adults with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, ESR1-mutated advanced or metastatic breast cancer, as detected by an FDA-authorized test, with disease progression following at least one line of endocrine therapy. 

On March 25, 2026, the Food and Drug Administration approved relacorilant (Lifyorli, Corcept Therapeutics Inc.), a glucocorticoid receptor antagonist, in combination with nab-paclitaxel for the treatment of adults with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received one to three prior systemic treatment regimens, at least one of which included bevacizumab.

On March 20, 2026, the Food and Drug Administration approved nivolumab (Opdivo, Bristol Myers Squibb Company) with doxorubicin, vinblastine, and dacarbazine (AVD) for adult and pediatric patients 12 years and older with previously untreated, Stage III or IV classical Hodgkin lymphoma (cHL).

On March 5, 2026, the Food and Drug Administration approved teclistamab (Tecvayli, Janssen Biotech, Inc.) in combination with daratumumab hyaluronidase-fihj for adult patients with relapsed or refractory multiple myeloma who have received at least one prior line of therapy including a proteasome inhibitor and an immunomodulatory agent. 

On February 26, 2026, the Food and Drug Administration granted accelerated approval to zongertinib (Hernexeos, Boehringer Ingelheim Pharmaceuticals, Inc.), a kinase inhibitor, for an expanded indication for adults with unresectable or metastatic non-squamous non-small cell lung cancer (NSCLC) whose tumors have HER2 (ERBB2) tyrosine kinase domain (TKD) activating mutations, as detected by an FDA-authorized test.

On February 24, 2026, the Food and Drug Administration granted traditional approval to encorafenib (Braftovi, Array BioPharma Inc., a subsidiary of Pfizer Inc.) in combination with cetuximab and fluorouracil-based chemotherapy for the treatment of adult patients with metastatic colorectal cancer (CRC) with a BRAF V600E mutation, as detected by an FDA-authorized test. Encorafenib received accelerated approval in combination with cetuximab and mFOLFOX6 for metastatic colorectal cancer with BRAF V600E mutation in 2024. 

On February 19, 2026, the Food and Drug Administration approved acalabrutinib (Calquence, AstraZeneca) tablets and capsules in combination with venetoclax (Venclexta, AbbVie Inc. and Genentech Inc.) for adults with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).

On February 10, 2026, the Food and Drug Administration approved pembrolizumab (Keytruda, Merck) as well as pembrolizumab and berahyaluronidase alfa-pmph (Keytruda Qlex, Merck) in combination with paclitaxel, with or without bevacizumab, for adult patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal carcinoma whose tumors express PD-L1 (CPS≥1) as determined by an FDA-authorized test, and who have received one or two prior systemic treatment regimens.

On January 27, 2026, the Food and Drug Administration approved daratumumab and hyaluronidase-fihj (Darzalex Faspro, Janssen Biotech, Inc.) in combination with bortezomib, lenalidomide, and dexamethasone (VRd) for adults with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant (ASCT).

On December 17, 2025, the Food and Drug Administration approved amivantamab and hyaluronidase-lpuj (Rybrevant Faspro, Janssen Biotech, Inc.) for subcutaneous injection for adult patients across all indications approved for the intravenous formulation of amivantamab (Rybrevant, Janssen Biotech, Inc.). See the prescribing information for the specific indications.

On December 17, 2025, the Food and Drug Administration approved rucaparib (Rubraca, pharmaand GmbH) for adults with a deleterious BRCA mutation (BRCAm) (germline and/or somatic)-associated metastatic castration-resistant prostate cancer (mCRPC) previously treated with an androgen receptor-directed therapy. Patients should be selected for therapy using an FDA-approved companion diagnostic (CDx).

On December 15, 2025, the Food and Drug Administration approved fam-trastuzumab deruxtecan-nxki (Enhertu, Daiichi Sankyo, Inc.) in combination with pertuzumab for the first-line treatment of adults with unresectable or metastatic HER2-positive (IHC 3+ or ISH+) breast cancer as determined by an FDA-approved test.

On December 12, 2025, the Food and Drug Administration approved niraparib and abiraterone acetate (Akeega, Janssen Biotech, Inc.) with prednisone for adults with deleterious or suspected deleterious BRCA2-mutated (BRCA2m) metastatic castration-sensitive prostate cancer (mCSPC), as determined by an FDA-approved test.

On December 4, 2025, the Food and Drug Administration approved lisocabtagene maraleucel (Breyanzi, Juno Therapeutics, Inc., a Bristol-Myers Squibb Company) for adults with relapsed or refractory marginal zone lymphoma (MZL) who have received at least two prior lines of systemic therapy

On December 3, 2025, the Food and Drug Administration granted traditional approval to pirtobrutinib (Jaypirca, Eli Lilly and Company) for adults with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) who have previously been treated with a covalent BTK inhibitor. In 2023, FDA granted accelerated approval to pirtobrutinib for adults with CLL/SLL who have received at least two prior lines of therapy, including a BTK inhibitor and a BCL-2 inhibitor.

Eur J Histochem. 2024 Jul 22;68(3):4048. doi: 10.4081/ejh.2024.4048.
Li XB, Li JL, Wang C, Zhang Y, Li J

Diabetes Care. 2026 Jun 1;49(6):901-905. doi: 10.2337/dci26-0068.
Kahn SE, Anderson CAM, Buse JB, Selvin E

N Engl J Med. 2026 May 31. doi: 10.1056/NEJMoa2605555.
O'Reilly EM, Wainberg ZA, Hendifar AE, Borad MJ, Pietrantonio F, Pant S, Hammel P, Cremolini C, Manji GA, Oberstein PE, Garrido-Laguna I, Springfeld C, Azad NS, Ueno M, Chui SY, Zhang Y, Patel H, Lee Y, Salman Z, Wolpin BM; RASolute 302 Trial Investigators

Lancet Infect Dis. 2026 Jun 2:S1473-3099(26)00194-5. doi: 10.1016/S1473-3099(26)00194-5.
GBD 2023 Diarrhoeal Disease and Enteric Infectious Diseases Collaborators

N Engl J Med. 2026 Jun 4. doi: 10.1056/NEJMoa2604625.
Heerspink HJL, Neuen BL, Agarwal R, Cherney DZI, Lam CSP, Tuttle KR, Wanner C, Sarafidis P, Jongs N, Smeijer JD, Brinker M, Rethemeier N, Schloemer P, Vesterinen P, Goldsbury D, Dizayee S, Mares JW, Perkovic V; FIND-CKD Investigators

JAMA. 2026 Jun 5:e269923. doi: 10.1001/jama.2026.9923.
Neuen BL, Perkovic V, Agarwal R, Cherney DZI, Lam CSP, Wanner C, Tuttle KR, Sarafidis P, Barratt J, Burgner A, Chen X, Chew-Wong A, Dobronravov VA, Floege J, McCafferty K, Nangaku M, Packham D, Papachristou E, Pergola PE, Speeckaert MM, Subbiah A, Tang SCW, Tang S, Yeo SC, Jongs N, Smeijer JD, Berger M, Brinker M, Dayoub R, Elliott J, Li N, Mueller K, Rethemeier N, Finkelsztein MY, Heerspink HJL; FIND-CKD Investigators

JMIR Res Protoc. 2026 Jun 5;15:e80546. doi: 10.2196/80546.
Ngo VK, Vu TT, Sobowale K, Lam TT, Nguyen T, Linnemayr S, Huang W

Cell. 2026 Jun 4:S0092-8674(26)00522-2. doi: 10.1016/j.cell.2026.05.005.
Pandya T, Zagorulya M, Leung MM, Augustine M, Liu LY, Leppä AM, Baruchel U, Ng SW, Klockner T, Mugabo M, Griffen AJ, Blyuss O, Iliakis CS, Grenov A, Haase K, Muller DC, Chan KH, Wu J, Burk VA, Wright N, Le Marois A, Pazukhina E, Ward S, Slawinski H, Pelletier M, Murphy C, Park MD, Snoeks T, Suarez-Bonnet A, Priestnall SL, Hardas A, Grieco C, Archer A, Celik A, Jimenez-Sanchez A, Scott R, Zahed H, Montégut L, Meza R, Durney CH, Lam S, Karasaki T, Vermeulen RCH, Xu H, Serrano-Fernandez P, Crnogorac-Jurcevic T, Menon U, Apostolidou S, Zaikin A, Gunu R, Whitwell HJ, Huang Z, Li Z, Hu X, Zhu B, Li L, Chirlaque MD, Guevara M, Kolijn PM, Guenoun A, Mookherjee N, Johansson M, Wang Z, Chatterjee N, Chiu CH, Chen Z, Pe'er D, Sahai E, Freytag S, Wack A, Gunter MJ, Merad M, Zhang J, Carlsten C, Yang PC, Chen HY, Platz EA, LaFave LM, Smith-Byrne K, Jamal-Hanjani M, Litchfield K, Nene NR, McGranahan N, Grönroos E, Hill W, Weeden CE, Swanton C

Nature. 2026 Jun 3. doi: 10.1038/s41586-026-10597-2.
Li M, Yu X, Ouyang S, Chen X, Yu H, Liu Y, Li Z, Yu C, Kang R, Gaillet C, Colombeau L, Rodriguez R, Song L, Kroemer G, Tang D, Li J

Radiographics. 2009 Sep-Oct;29(5):1525-30. doi: 10.1148/rg.295085215.
Farsad K, Kattapuram SV, Sacknoff R, Ono J, Nielsen GP

Lancet. 2026 Jun 6:S0140-6736(26)00967-0. doi: 10.1016/S0140-6736(26)00967-0.
Bajaj HS, Welch M, Shah P, Luna E, Jaouimaa FZ, Liu B, Liu R, Chen Y, Patel H, Bartee A

Lancet. 2026 Jun 5:S0140-6736(26)01009-3. doi: 10.1016/S0140-6736(26)01009-3.
Neuen BL, Heerspink HJL, Perkovic V, Cherney DZI, Lam CSP, Tuttle KR, Wanner C, Sarafidis P, Anker SD, Filippatos G, Pitt B, Rossing P, Ruilope LM, Jongs N, Smeijer JD, Brinker M, Ahlers C, Lage A, Horvat-Bröcker A, Schloemer P, Eissing T, Dayoub R, Lawatscheck R, Agarwal R; FIND-CKD, FIDELIO-DKD and FIGARO-DKD Investigators

Methods Mol Biol. 2002;186:233-40. doi: 10.1385/1-59259-173-6:233.
During A, Nagao A, Smith JC Jr

Thyroid. 2026 May;36(5):481-544. doi: 10.1177/10507256261445624. Epub 2026 May 31.
Korevaar TIM, Leung AM, Alexander EK, Bliddal S, Boelaert K, Brenta G, Chou R, Dhillon-Smith R, Dosiou C, Eaton JL, Guan H, Kilpatrick SJ, Lasserre BJ, Lee SY, Maraka S, Meister KD, Morris-Wiseman LF, Nguyen CT, Pearce EN, Shan Z

Eur Heart J. 2026 Jun 5:ehag372. doi: 10.1093/eurheartj/ehag372.
Zhang H, Sun L, Xu T, Hou X, Zhong F, Shi F, Chen Y, Li Y, Wang Y, Lyu Y, Zhang W, Fu Y, Zhao Y, Yuan A, Chen L, Ji Y, Wang M, Lu B, Pu J

Nat Genet. 2026 Jun 3. doi: 10.1038/s41588-026-02583-1.
EADB; EADI; Bonn; ADGC; CHARGE; FinnGen; GERAD; GR@ACE/DEGESCO; PGC-ALZ

Lancet Respir Med. 2026 Jun 5:S2213-2600(26)00094-9. doi: 10.1016/S2213-2600(26)00094-9.
Solomon JJ, Dieudé P, Matson SM, Lee JS, Rojas-Serrano J, Sebastiani M, Gonzalez A, Demoruelle MK, Hoffman-Vold AM, Kam MLW, Swigris JJ, Sparks JA, Brown KK, Cottin V, Kellermeyer LM, Wilson KC, Waseda Y, Crestani B, Walsh SLF, Poletti V, Doyle T, Koduri G, Kelly C, Danoff S, Dellaripa PF

Science. 2026 Jun 4;392(6802):eaed8630. doi: 10.1126/science.aed8630. Epub 2026 Jun 4.
Yu M, Wang J, Zhai Z, Huang R, Fan G, Su X, Niu Y, Zhu H, Chen J, Jiang G, Zhang T, Zhong Y, Lei B

N Engl J Med. 2000 Nov 23;343(21):1506-13. doi: 10.1056/NEJM200011233432101.
Kannus P, Parkkari J, Niemi S, Pasanen M, Palvanen M, Järvinen M, Vuori I

Gynecol Oncol. 2026 Jun 5;210:153-173. doi: 10.1016/j.ygyno.2026.05.022.
Nelson G, Altman AD, Metcalfe A, Fotopoulou C, Taylor J, Glaser G, Bakkum-Gamez J, Kumar A, Meyer LA, Stone R, Mena G, Elias KM, Bisch SP, Zivanovic O, Miralpeix E, Bhandoria G, Eriksson AGZ, Ruzycki SM, Sultan P, Sauro KM, Blake L, Brindle ME, Ramirez PT, Dowdy SC